Eledon Pharmaceuticals (ELDN) Competitors $2.87 -0.13 (-4.33%) Closing price 04:00 PM EasternExtended Trading$2.97 +0.10 (+3.48%) As of 07:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ELDN vs. IMTX, GYRE, DAWN, VIR, AVXL, ABUS, EOLS, KALV, ANAB, and COGTShould you be buying Eledon Pharmaceuticals stock or one of its competitors? The main competitors of Eledon Pharmaceuticals include Immatics (IMTX), Gyre Therapeutics (GYRE), Day One Biopharmaceuticals (DAWN), Vir Biotechnology (VIR), Anavex Life Sciences (AVXL), Arbutus Biopharma (ABUS), Evolus (EOLS), KalVista Pharmaceuticals (KALV), AnaptysBio (ANAB), and Cogent Biosciences (COGT). These companies are all part of the "pharmaceutical products" industry. Eledon Pharmaceuticals vs. Its Competitors Immatics Gyre Therapeutics Day One Biopharmaceuticals Vir Biotechnology Anavex Life Sciences Arbutus Biopharma Evolus KalVista Pharmaceuticals AnaptysBio Cogent Biosciences Eledon Pharmaceuticals (NASDAQ:ELDN) and Immatics (NASDAQ:IMTX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, community ranking, media sentiment, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership. Do institutionals and insiders believe in ELDN or IMTX? 56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. Comparatively, 64.4% of Immatics shares are owned by institutional investors. 12.3% of Eledon Pharmaceuticals shares are owned by insiders. Comparatively, 3.3% of Immatics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the MarketBeat Community prefer ELDN or IMTX? Immatics received 4 more outperform votes than Eledon Pharmaceuticals when rated by MarketBeat users. Likewise, 74.42% of users gave Immatics an outperform vote while only 70.00% of users gave Eledon Pharmaceuticals an outperform vote. CompanyUnderperformOutperformEledon PharmaceuticalsOutperform Votes2870.00% Underperform Votes1230.00% ImmaticsOutperform Votes3274.42% Underperform Votes1125.58% Do analysts rate ELDN or IMTX? Eledon Pharmaceuticals presently has a consensus price target of $12.50, indicating a potential upside of 335.54%. Immatics has a consensus price target of $14.67, indicating a potential upside of 139.65%. Given Eledon Pharmaceuticals' higher possible upside, research analysts clearly believe Eledon Pharmaceuticals is more favorable than Immatics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eledon Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Immatics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Does the media refer more to ELDN or IMTX? In the previous week, Immatics had 4 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 9 mentions for Immatics and 5 mentions for Eledon Pharmaceuticals. Immatics' average media sentiment score of 1.04 beat Eledon Pharmaceuticals' score of 0.68 indicating that Immatics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eledon Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Immatics 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, ELDN or IMTX? Eledon Pharmaceuticals has a beta of -0.17, suggesting that its stock price is 117% less volatile than the S&P 500. Comparatively, Immatics has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500. Is ELDN or IMTX more profitable? Eledon Pharmaceuticals has a net margin of 0.00% compared to Immatics' net margin of -47.94%. Immatics' return on equity of -15.90% beat Eledon Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Eledon PharmaceuticalsN/A -189.99% -28.17% Immatics -47.94%-15.90%-9.38% Which has preferable valuation and earnings, ELDN or IMTX? Immatics has higher revenue and earnings than Eledon Pharmaceuticals. Immatics is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEledon PharmaceuticalsN/AN/A-$116.54M-$2.10-1.37Immatics$144.15M5.16-$104.98M-$0.17-36.00 SummaryImmatics beats Eledon Pharmaceuticals on 14 of the 18 factors compared between the two stocks. Get Eledon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ELDN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ELDN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELDN vs. The Competition Export to ExcelMetricEledon PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$171.86M$6.85B$5.56B$8.50BDividend YieldN/A2.53%5.28%4.16%P/E Ratio-1.438.4326.6419.64Price / SalesN/A262.52407.99152.17Price / CashN/A65.8538.2534.64Price / Book9.576.536.974.60Net Income-$116.54M$143.25M$3.23B$248.06M7 Day Performance-6.82%0.21%-0.98%-1.03%1 Month Performance-1.03%10.92%7.70%3.50%1 Year Performance-2.38%2.44%31.32%12.68% Eledon Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELDNEledon Pharmaceuticals2.586 of 5 stars$2.87-4.3%$12.50+335.5%+1.4%$171.86MN/A-1.4310Positive NewsIMTXImmatics2.6034 of 5 stars$6.01+11.5%$14.67+144.0%-53.2%$730.52M$144.15M-9.11260Analyst RevisionGap UpHigh Trading VolumeGYREGyre Therapeutics0.3177 of 5 stars$7.68-15.3%N/A-24.0%$720.06M$100.64M384.0040Short Interest ↓High Trading VolumeDAWNDay One Biopharmaceuticals1.6141 of 5 stars$7.01+9.9%$30.57+336.1%-48.5%$710.55M$161.92M-6.8160VIRVir Biotechnology2.9976 of 5 stars$5.07+2.6%$32.86+548.1%-50.2%$700.87M$14.30M-1.29580Positive NewsGap DownAVXLAnavex Life Sciences3.8723 of 5 stars$7.56+0.4%$44.00+482.0%+119.2%$645.41MN/A-13.7540Positive NewsGap DownABUSArbutus Biopharma2.2088 of 5 stars$3.36flat$5.50+63.7%+10.2%$643.53M$6.40M-7.8190Positive NewsEOLSEvolus4.0609 of 5 stars$9.97+8.5%$23.75+138.2%-11.7%$642.83M$275.46M-10.96170Positive NewsInsider TradeHigh Trading VolumeKALVKalVista Pharmaceuticals4.0144 of 5 stars$12.92+9.5%$24.83+92.2%+6.0%$642.33MN/A-3.55100Trending NewsInsider TradeAnalyst RevisionHigh Trading VolumeANABAnaptysBio1.7625 of 5 stars$21.86-1.7%$40.38+84.7%-2.9%$642.25M$111.87M-3.60100COGTCogent Biosciences2.5119 of 5 stars$5.61+3.1%$14.57+159.7%-20.1%$638.73MN/A-2.2680Positive NewsGap DownHigh Trading Volume Related Companies and Tools Related Companies IMTX Competitors GYRE Competitors DAWN Competitors VIR Competitors AVXL Competitors ABUS Competitors EOLS Competitors KALV Competitors ANAB Competitors COGT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ELDN) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket ch...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eledon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eledon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
